StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)

Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –

TG Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

TG Therapeutics's enterprise value was $10.20B on Nov 11, 2026, against $5.23B a year earlier. Over the last 5 years it ranged from $400.85M to $10.20B, with a median of $3.52B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$10.20B+117.3%
2025Dec 31, 2025$4.69B+2.2%
2024Dec 31, 2024$4.59B+86.9%
2023Dec 29, 2023$2.46B+54.2%
2022Dec 30, 2022$1.59B-32.2%
2021Dec 31, 2021$2.35B-63.7%
2020Dec 31, 2020$6.48B+530.0%
2019Dec 31, 2019$1.03B+324.7%
2018Dec 31, 2018$242.28M-50.3%
2017Dec 29, 2017$487.55M+151.6%
2016Dec 30, 2016$193.77M-62.1%
2015Dec 31, 2015$511.13M-13.2%
2014Dec 31, 2014$589.12M+615.4%
2013Dec 31, 2013$82.35M+40.7%
2012Dec 31, 2012$58.51M+253.8%
2011Dec 30, 2011$16.54M–

More TG Therapeutics figures

See a number that looks wrong?